Inclusion Criteria:

• - Subject's written informed consent obtained prior to any study-related procedure.

• - Males or females, of any race, aged ≥ 40 years of age.

• - Body weight ≥ 45 kg.

• - Diagnosis of IPF as defined by current American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association guidelines.

Diagnosis of IPF must be within the past 5 years prior to enrolment, and in the opinion of the Investigator, has been stable for at least 3 months.

• - Subjects not receiving any IPF treatment (including subjects with previous use of antifibrotic treatment that has been stopped for at least 2 weeks prior to screening) or receiving well-tolerated standard of care approved treatments at a stable dose for at least 8 weeks prior to screening (nintedanib or pirfenidone) and it is anticipated the dose will remain unchanged throughout the study.

• - Forced vital capacity (FVC) ≥ 50% of predicted and ratio of forced expiratory volume in the first second (FEV1)/FVC ≥ 0.7 at screening.

• - Diffusing capacity of the lung for carbon monoxide (DLCO; corrected for haemoglobin) ≥ 35% at screening.

• - Able to understand the study procedures and the risks involved.

• - Male and Female subjects following contraceptive requirements detailed in the study protocol.

Exclusion Criteria:

• - History of lower respiratory tract infection within 4 weeks prior to screening and up to Day 1 of the study.

• - History of acute exacerbation of IPF within 3 months prior to screening and up to Day 1 of the study.

• - Active diagnosis of lung cancer or a history of lung cancer.

• - Active cancer or a history of cancer (other than lung cancer) with less than 5 years disease free survival time (whether or not there is evidence of local recurrence or metastases).

• - Infiltrative lung disease other than IPF.

• - Subjects exhibiting unhealed wounds or foot ulcers or have known history of wound healing complications.

• - Chronic heart failure categorized as New York Heart Association Class II, III, or IV; clinical diagnosis of cor pulmonale requiring specific treatment; or severe pulmonary hypertension.

• - Currently receiving, or have received, a systemic corticosteroid, immunosuppressant, cytotoxic therapy, vasodilator therapy for pulmonary hypertension, or unapproved or investigational treatment for IPF within 4 weeks prior to screening or prior to randomization.

• - Coronavirus disease-2019 (COVID-19) vaccine at least 7 days before dosing.

Any systemic symptoms (e.g. myalgia, fever, chills, fatigue, etc.) after COVID-19 vaccine should subside at least 2 days before the Day 1 visit.

• - Documented COVID-19 diagnosis within the last 4 weeks or which has not resolved within 7 days prior to screening or before treatment.

• - Known intolerance and/or hypersensitivity to any of the excipients contained in the formulation or any other substance used in the study.

• - History of allergic or anaphylactic reaction to human, humanised, chimeric, immunoglobulins (Igs), or murine monoclonal antibodies.

• - Clinically relevant abnormal laboratory values (clinical chemistry and haematology) at screening suggesting an unknown disease and requiring further clinical investigation or which may impact the safety of the subject or the evaluation of the study results according to Investigator judgement.

.

• - Pregnant or lactating women.

The principal aim of this study is to obtain safety and tolerability data when CHF10067 is administered intravenously as single ascending doses to subjects with IPF. This information, together with the pharmacokinetic (PK) and immunogenicity data, will help establish the doses suitable for future studies in subjects. The effect of CHF10067 on TG2 levels will also be investigated as an exploratory endpoint. A sequential group, single ascending dose design has been chosen for safety reasons because CHF10067 is in the early stages of clinical development and no data in the IPF population has been collected so far. In addition, sentinel dosing will be used so that in each cohort 2 subjects (1 CHF10067 and 1 placebo) will be dosed at least 24 hours before the remaining 6 subjects. The study will be double-blind and placebo-controlled to avoid bias in the collection and evaluation of data during its conduct. Placebo has been chosen as the comparison treatment to assess whether any observed effects are treatment-related or simply reflect the study conditions.

Arms

Experimental: Test Treatment

A single intravenous (IV) dose of CHF10067

Placebo Comparator: Reference treatment

A single dose of placebo (commercial source of 0.9% sodium chloride aqueous solution)

Interventions

Biological: - CHF10067 starting dose

Intravenous administration of a starting dose of the monoclonal antibody

Biological: - CHF10067 intermediate dose

Intravenous administration of an intermediate dose of the monoclonal antibody

Biological: - CHF10067 high dose

Intravenous administration of a high dose of the monoclonal antibody

Drug: - Placebo

Intravenous administration of a physiological solution as placebo.